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Introduction
In recent decades, social networks research has contributed to important gains in knowledge 
critical to programs designed to decrease the spread of infectious diseases (i.e. HCV, HIV 
and other STIs), to chronic conditions (i.e. tobacco use and obesity) ( Flath et al., 2018; 
Maddox et al., 2014; Morris, 2004; Luke & Harris, 2007; Rothenberg et al., 1998; Thomas 
W. Valente, Gallaher, & Mouttapa, 2004; Thomas W. Valente & Pitts, 2017; Williams et al. 
2019; Wu et al. 2018). The relational data collected through social network analysis (Tubaro, 
2014) is particularly important for epidemiological research, mapping how a virus or 
infectious diseases spread from one person to another within a particular group (Smith & 
Christakis, 2008).
Social network studies have been particularly critical in demonstrating how the sharing of 
drug injection equipment contributes to HIV risk among people who inject drugs (PWID) 
(Gosh et al., 2017; Bogart et al., 2018; Latkin et al., 2018). Other social network studies 
have demonstrated that PWID were more likely to share needles and injection equipment 
with those users with whom they were strongly socially connected, rather than with mere 
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acquaintances or those with whom they had weak connections (De et al., 2007; Rudolph et 
al., 2017).
Recently, studies have shown that similar social network dynamics underpin the emergence 
of a HCV epidemic among PWID (Hellard et al., 2014; Pilon et al., 2011; Rolls et al., 2013). 
Social network analysis has been employed not only to illustrate how individual and 
structural factors can contribute to HIV and HCV risk behaviors in this group, but also to 
model the evolution of HIV and HCV epidemics among PWID and to formulate evidence 
based prevention and treatment strategies (Mateu-Gelabert et al., 2018). One important 
contribution of social network health research to behavioral, epidemiological, or qualitative 
HIV research is the ability to understand the social pattern of infectious diseases within 
impoverished and marginalized communities.
In turn, the relational quality of social network research, which is one of its main strengths, 
also presents particular ethical challenges. As detailed by Borgatti and Molina (2005), 
conducting social network research is different from traditional research, where participants 
report on themselves. Instead, participants in network studies report not only on themselves 
but also on others, who in turn provide the names of other individuals in their social 
network. Thus social network research raises unique privacy, confidentiality, and anonymity 
challenges, since there is no clear mechanism for securing the consent of individuals named 
by participants. This also presents challenges for Ethics Review Boards (IRBs), since 
traditional requirements for informed consent of “named” participants could bring this 
scientifically critical type of research to a halt (Klovhdal, 2005).
The ethical challenges regarding privacy protections in social networks research continues to 
evolve with the emergence of new technologies. Social networks health research involving 
social media has prompted renewed concerns about privacy, confidentiality and anonymity 
Hibbin et al. 2018; Hokke et al. 2018; Lunnay et al. 2015; Samuel & Buchanan 2020; Sellers 
et al. 2020).
Researchers and bioethicists tend to interpret privacy and confidentiality by taking into 
consideration only their own obligations. However, an account of how study participants 
understand privacy and confidentiality or the role these considerations play in their decision-
making process is lacking. While the research experiences of people who inject drugs have 
received some examination (Davidson & Page, 2012; Scott, 2008;), this is to our knowledge 
this is the first empirical study documenting how PWID involved in a social network study 
understand ethical obligations derived from their participation. By drawing on the 
experiences of PWID previously enrolled in a large-scale study of social networks and 
HIV/HCV risk in rural Puerto Rico, this paper explores the participants’ perspectives on 
privacy and confidentiality. Understanding how vulnerable populations perceive norms 
around HIV disclosure within their social network will contribute to the conduct of research 
in a way experienced as acceptable for participants. One strength of this study is that its 
participants’ views are shaped by their actual experience of having been enrolled in a social 
network study. Using qualitative methods involving 40 semi-structured interviews with 
active PWID 18 years old and older, we documented participants’ views regarding the 
privacy and confidentiality issues raised by their engagement in social network research.
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Data presented in this paper were from measures embedded in a larger study, in which 
participants’ views on research trust and attitudes toward financial compensation were also 
examined (Abadie, Brown, & Fisher, 2019; Abadie, Goldenberg, Welch-Lazoritz & Fisher, 
2018). This study focuses on how people who inject drugs view confidentiality and 
disclosure obligations when individuals within their social network are perceived as 
violating community norms. The purpose of this research is to (1) identify community 
norms on HIV disclosure in the course of social network studies with people who inject 
drugs, (2) motivate ethical deliberation around these issues, and (3) inform best research 
ethics practices through consideration of study participant’s values.
Participants
This study was nested within an ongoing, multi-year NIH/NIDA funded parent project on 
Social Networks and HIV/HCV risk in among PWID residing in the localities of Cidra, 
Cayey, Aguas Buenas, and Comerio, in rural Puerto Rico. Data collection for the Social 
Network study was conducted between April 2015 and April 2017 and included N=360 
active PWID 18 ≥ years old. Details about the methodology, including recruitment strategy 
and sample composition, have been published elsewhere (Abadie, et al., 2016; Abadie, et al. 
2017). To document participants’ views about confidentiality, we conducted semi-structured 
interviews (N=40) with a subsample of participants in the Social Network study. This was a 
convenience sample, with all the attendant limitations, but the broad inclusion criteria helped 
ensure sampling of participants from different sociodemographic backgrounds and substance 
abuse profiles. Since people who inject drugs in rural Puerto Rico are overwhelmingly male, 
we decided not to include women in our convenience sample. We address the effects of this 
selection in the limitation section.
We secured approval from two Ethics Review Boards (IRBs) for the present research. 
Participants provided written consent prior to enrollment in the study. To protect 
confidentiality participants were identified through the same identification and coupon 
number assigned for the parent study, which also facilitated linkage of participant data to 
data gathered through the parent study (e.g., demographics, HIV/HCV status, polysubstance 
and injection drug use, and injection risk behaviors). A Community Advisory Board (CAB) 
of eight active PWID who had participated in the parent study was established prior to 
commencement of data collection. Input of the CAB was sought in drafting the recruitment, 
consent and interview procedures, to ensure their cultural appropriateness and sensitivity to 
our study population.
Interview Format
With the permission of participants all semi-structured in-depth interviews were audio-taped 
at the research office site in Cidra, a location already familiar to study participants. The first 
section of the semi-structured interviews collected demographic data such as age, education, 
income, costs of acquiring drugs, frequency of drug use and access to health care. We also 
collected data about HIV/HCV status and injection risk behaviors. To explore participants’ 
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attitudes toward confidentiality as well as their views of disclosure obligations when 
somebody in their social network violates social or community norms, we asked them to 
respond to a vignette asking participants how the principal investigator of a study should 
proceed if he/she learned that a HIV positive participant in his/her study shared injection 
materials with other participants in the study. One of the strengths of this vignette is that it 
presented a realistic scenario for respondents, since all had previously enrolled in the parent 
social network study that had tested them for HIV/HCV and had also gathered data on who 
had injected or shared injection equipment with whom.
Data analysis
Interviews were transcribed, and all personal identifiers were removed. Codes were 
developed to convey the wide array of themes present in the narratives. An audit trail was 
maintained to keep track of how and why analytic decisions were made, and a codebook was 
developed to describe and define all study codes. These codes were iteratively revised and 
regrouped until they eventually represented a set of higher-level axial codes 
comprehensively describing participants’ understandings of confidentiality and disclosure 
obligations in the context of social network health research.
Results
Demographic Information
The sociodemographic profile of participants enrolled in the current study shows that all are 
males with a median age of 42.4 years and a median number of 22.5 years spent injecting 
drugs. Only one in twenty (5%) were HIV-seropositive; a large majority were HCV-
seropositive (78%). All participants reported having previously experienced incarceration, 
and the majority were unemployed (87.5%). Only half had a high school or greater level of 
educational attainment. Approximately half had never been married, and all participants in 
our sample self-identified as heterosexuals. Finally, a little more than half injected four times 
or more a day (55%), and one-third injected two to three times a day (30%). Few reported 
having participated in a research study other than the parent study from which they had been 
recruited (7.5%).
Major Themes
“This is between you and me.”: Investigator confidentiality obligations—
Participants express strong views about protecting their confidentiality as research subjects. 
In contrast to PWID in urban areas where interactions can be more impersonal or even 
anonymous, PWID in rural areas have very deep personal, and in some cases even familiar 
connections with each other. In this context, confidentiality of HIV and HCV results 
becomes paramount since the lack of confidentiality can impact not only an individual, but 
everybody that is involved in his or her network, something Flaco Pablito [not his real name. 
All names reported in the results are pseudonyms] is very aware of:
“If they tell me that it is confidential, we’ll go everywhere, you know, but if it is not 
and it leaks to a third, a fourth, a fifth that might have the opportunity to learn 
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things one tells you for example, or the results [of the tests], that is not right. This is 
between you and me.”
Confidence that confidentiality would be protected, was not assumed, but was a result of the 
participant’s experience sharing their information with investigators.
“I trusted you because you conducted the tests and it didn’t go out there, it stayed 
there. If the result was positive, it stayed there, if it was negative, it stayed there, it 
didn’t go out there, nobody knew this information. I trusted you because what we 
said in the office stayed there, it was confidential. The fact that it was confidential 
made me trust your study more.” Miguelito
Despite the fact that most participants have not engaged previously in community health 
research, they demonstrated a good understanding of the meanings of confidentiality: 
“nobody else knows” the tests results”:
“Yes, yes, it was very important [confidentiality] it was an additional layer of 
reassurance that you are giving me that [survey responses and test results] are 
confidential, nobody else knows them”. Vitin
For some, the understanding of confidentiality was not necessarily shaped by previous 
research engagements, but through their experiences navigating the health care system, 
where most were very familiar with the Health Insurance Portability and Accountability Act 
(HIPAA), protecttions of patient medical information:
“Right now, you go to a hospital and none of them can divulge… [your medical 
record], they can’t say anything else. That’s HIPAA law, if they divulge anything 
then you can sue them, you can do a lot of things. I think that his study is like that 
and it gives me peace of mind.” Papo.
“He’s under oath”: Attitudes toward disclosure of HIV status.—To explore the 
meanings of confidentiality in this population we provided a dilemma adapted from Fisher 
(2011): “A researcher knows that an HIV positive participant in his study is sharing 
syringes/works with another participant in the study without disclosing this information to 
him/her. Should the investigator tell the other participant or not?”
The responses were divided in two distinct camps. One group of participants felt that the 
confidentiality was paramount and should not be broken under any circumstances while the 
other group felt that the HIV+ participant was placing others at risk and that this fact 
justified the elimination of confidentiality. Yet, participants’ reasoning went beyond the yes 
or no answer, both groups recognized the complexity of the issue and came up with potential 
solutions to the problem or further elaborated their views, illustrating the multiple 
dimensions behind disclosure of confidential results that reflected both responsibilities of the 
investigator and participants. Miguelito presents a straightforward answer to this question. 
The investigator should not intervene. It’s the participant that needs to be upfront and tell the 
other: “Look, I have this, I can’t share anything [with you]. You’ve been warned, now if you 
want to share that’s on you. The participant that has HIV has to speak clearly, and if he 
doesn’t then it is something that both will need to sort out…
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Landi espouses a more restricted view, that of confidentiality being an absolute principle that 
should be respected because “that’s the way it should be”: “No, because if it is confidential, 
then it’s confidential. The researcher can’t say anything. […] But the researcher should not 
intervene, it is confidential, and that’s the way it should be. He can’t tell.”
Papo agrees with the latter view but also understands the predicament the researcher is in—
that, being bound by the confidentiality requirements, he should not disclose information 
that might save participants’ lives. The researcher, in his view, is “like a priest” during 
confession, who “can’t say nothing because he’s under oath”:
P: If you see that the person is not going to say anything and it’s f..king up the other and the 
researcher knowing this… if I were the researcher, I would tell because if not the other will 
keep hurting other people.
I: But you know that the researcher promised everybody that the test results are confidential.
P: But if you see that the person is not helping. You see that it is hurting, I would break the 
promise because I wouldn’t see that he keeps hurting and hurting. Then, this one comes and 
fucks one, and then another one and then he keeps going. he’s going to keep hurting others. 
The researcher might get into trouble by violating the confidentiality. It is like a priest, you 
go and confess and then he can’t say nothing because he’s under oath.
I: You think the researcher is like a priest?
P: Yes, it has to be kept secret.
On the other hand, another group of participants felt that the confidentiality protections 
should be lifted if participants’ health and well-being were at risk. Cesar illustrates this 
position, though noting that lifting confidentiality arrangements would be “sad and 
regretful”:
On the other hand, another group of participants felt that the confidentiality protections 
should be lifted if participants’ health and well-being were at risk. Cesar illustrates this 
position, though noting that lifting confidentiality arrangements would be “sad and 
regretful”: “Yes. If the person with the condition is not been direct and is exposing 
somebody’s else health for the rest of his life. It is confidential, but the person is been 
widely imprudent and when you are not taking care of yourself or others, I understand that 
the researcher should intervene. It is sad and regretful, and I understand that it is an invasion 
of privacy, but the person has been irresponsible.
El Viejo also believes that the investigator should break confidentiality to avoid serious 
harms and that this intervention is ethically justified because the HIV patient is acting 
unethically. Furthermore, since HIV-positive PWID can share drugs safely, there is no reason 
not to disclose their status, providing a further justification to break the confidentiality 
agreement:
The investigator should approach the exposed participant and tell him: “Look, this guy has 
this, just in case he didn’t tell you.” I think that the investigator should tell because he 
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wouldn’t be violating anybody’s right. The person that is in the wrong is the patient that is 
sick and wants to kill the other. In some US states it’s a crime if an HIV-positive person 
knowingly transmits the disease to another one. The investigator should intervene to save a 
life. Let me tell you something, when I was in jail, I saw somebody share injection 
equipment with his nephew without telling him that he had AIDS. The nephew was 
insisting, insisting, and at the end he says, ‘OK! Get the damn syringe,’ and he gave the 
infected needle to his own nephew! If the investigator tells the participant [that the injection 
partner is HIV positive] and as a result he kills the other, that’s not the investigator’s fault. It 
is because he [the participant] felt used. If the other had disclosed his status, nothing would 
have happened. Do you remember Angel? He would tell everybody, and if somebody didn’t 
know about his status, he would tell them: “no, I would go first, gave me my dose first and 
then you throw away that needle. I have the condition.”
Luis initially agrees with the notion that the researcher should disclose the HIV status of a 
study participant, but when reminded of the researcher’s obligation to maintain 
confidentiality he advances a creative solution to the problem that enables the researcher to 
maintain confidentiality obligations while also safeguarding the well-being of study 
participants:
I. Should the researcher disclose the HIV status? Why?
Luis. Yes. To save a life.
I. But keep in mind that the researcher tells everybody that results are confidential.
Luis. Confidential. Well, then the best would be that you call the person that has an HIV-
positive result and tell him, with all due respect, you know that this is confidential, you know 
that your test result is positive, if you are going to do a “caballo” sharing drugs with others, 
why don’t you tell him the truth, that you have “la condicion,” HIV, so he can take care? 
Instead of the researcher telling the other person, he has a conversation with whoever tested 
positive. It stays confidential.
I. And if you were the person that is sharing drugs with the participant that tested HIV 
positive and the researcher does not tell you anything, how would this make feel?
L. I wouldn’t change my view of him because when one enters here the first thing that one is 
told is that everything is confidential. And you can’t divulge the lives of others.
Discussion
The narratives of PWIDs in this study demonstrate that participants value and expect 
investigators to honor obligations of privacy and confidentiality as a requirement for their 
enrollment in social network health research. Participants worry that confidential HIV tests 
results might become known by others in their social network or those in the community at 
large. Disclosure of HIV status or other confidential information within a tight social 
network can have serious consequences, from reinforcing stigmatization, to retaliatory 
violence (Conroy & Wong, 2015; Hammett et al., 2015; Yonah, Fredrick, & Leyna, 2014). 
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Yet as participants’ responses to the vignette illustrates, people who inject drugs approach 
ethical dilemmas faced by investigators through their own moral lens suggesting that privacy 
and confidentiality requirements might be waived if community norms have been violated or 
in order to protect the health and well-being of their members. As Luis’s response shows, 
study participants can adopt a pragmatic approach, taking contextual factors into 
consideration to produce a creative solution that simultaneously allows the researcher to 
maintain confidentiality obligations while also reducing the risk of HIV transmission and 
associated harms. This ability for moral lens should not be surprising; other studies confirm 
that lay members and, in particular, economically marginalized people who use drugs can 
engage in complex ethical deliberations (Fisher, et al., 2009; Fisher, 2011).
The empirical examination of privacy and confidentiality issues arising from social network 
research among people who inject drugs can be framed within a goodness-of-fit ethical 
framework (GFE) that conceptualizes participant protections in terms of the extent to which 
ethical procedures are fitted to the needs of the participant population (Fisher, 2015; Fisher 
& Goodman, 2009). The GFE’s conceptualization of confidentiality risks shifts judgments 
regarding ethical procedures away from an exclusive focus on the privacy vulnerabilities 
faced by PWID in their daily life and toward the implementation of specific ethical practices 
that minimize privacy risks, maximize privacy protections, and best advance science to 
inform population-sensitive interventions. This approach also suggests that researchers and 
bioethicists need to consider not only researcher obligations toward participants but, 
critically, the ways that study participants perceive confidentiality and privacy obligations. 
Failure to do so might be perceived as violating important community norms, resulting in a 
potential lack of trust. People who inject drugs expect that the researcher in the study will 
preserve their privacy and confidentiality unless there is an overwhelming reason to break 
this obligation. Yet, as studies on research trust have shown, trust building is not an event, 
like the signing of the consent form, but a social process in which both researcher and 
subject become aware of each other goals and can share some kind of common good. As 
research on trust has shown, research participants perceive trust as part of a reciprocal 
relationship, where both participants and researchers help each other in the pursuit of their 
particular goals (Collins et al., 2017; Guillemin et al., 2016; Morgan, Lee, & Sebar, 2015; 
Abadie, Shira Goldenberg, Melissa Welch-Lazoritz, & Fisher. 2018; Zamudio-Haas, 
Mahenge, Saleem, Mbwambo, & Lambdin, 2016, Reed, Fisher, Blankenship, West, & 
Khoshnood, 2017). In this context, research participants might support limiting privacy to 
preserve community norms or avoid larger harms. This is particularly important in social 
network studies which might require to identify not only participants’ names or identifiable 
information, but also non-anonymized data of alters in the social network. During HIV 
testing for the Social Network and HIV/HCV risk study, we conducted hundreds of tests, 
with an HIV prevalence close to 5%. Frequently we knew all the participants who had 
shared injection equipment with the HIV-positive participant. While maintaining 
participants’ confidentiality, our staff provided the standard safe injection recommendations 
but in addition suggested that HIV-positive participants refrain from sharing if possible. If 
avoiding sharing injection equipment was not feasible, participants were advised to disclose 
their HIV status to their partners if they had not done so already. This approach, which is 
very similar to one suggested by one of our participants, preserved our obligation toward 
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maintaining participants’ privacy and confidentiality while also minimizing community 
harms.
By documenting how PWID understand privacy and confidentiality in the context of social 
network research, this study contributes to larger debates about research ethics with 
marginalized populations. Findings suggest that participants understand that some 
constraints may exist regarding the protection of privacy and confidentiality in social 
network research but that they are willing to participate if trust in the researchers is present, 
if the study is perceived to contribute to the social good, and if it does not oppose 
community norms.
Limitations
While one of the strengths of this study is that participants’ views on privacy are based on 
their previous engagement in a large study of social networks and risk in Puerto Rico, we 
acknowledge that the sample size, while standard for qualitative inquiry, might produce 
more robust results were it larger and randomly selected. Another limitation is that, given the 
convenience sampling strategy employed, results cannot be generalized beyond this 
population. The fact that this study has not collected data about how women who inject 
drugs understand privacy in the context of the social network is another limitation. Our 
sample composition is entirely male; this choice reflects not only the demographic 
background in our parent study but also a more general distribution among PWID, who tend 
to be extremely gendered, with many more men than women choosing intravenous drug use, 
at least in the US and Western countries. This study only enrolled PWID that had 
participated in the parent study. It is possible that this selection could have introduced some 
selection bias: those prospective participants with serious privacy concerns might have 
refused to enroll in the parent study, and, therefore, their views would not have been taken 
into consideration in this study. It is possible that this bias might have eliminated more 
extreme privacy views in our sample. Finally, this study assumed that conducting social 
network studies with this vulnerable population was desirable, but it did not ask participants 
if they agreed with that assessment—for example, if they considered that the benefits of the 
study outweighed the risks. Finally, this study shows complex moral reasoning on privacy 
and consent among its participants, but it is possible that they might have benefited from the 
fact that they were responding not to hypothetical situations but from their actual 
experiences as research subjects.
Best Practices
Results show that people who inject drugs value and expect privacy and confidentiality in 
the course of social network studies research but might be willing to see investigators lift 
certain privacy rights in certain circumstances. Researchers and study participants might 
harbor different expectations around the perceived obligations related to the disclosure of 
HIV test results. To avoid conflicts or misunderstandings, confidentiality expectations about 
HIV/HCV test results should be clearly addressed during the consent process. Participants 
should be informed of the procedures adopted to maintain the privacy and confidentiality of 
medically sensitive information. The potential for conflicting perceived obligations between 
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the researchers’ duty to maintain confidentiality and participants’ expectations that privacy 
might be lifted to protect participant well-being in accordance with community norms 
should be addressed. While social network studies involving people who inject drugs are a 
small fraction of all epidemiological and community-based studies conducting HIV testing 
with vulnerable populations, researchers in these fields should be mindful of community 
norms around HIV disclosure. Clear communication of expectations about this issue is 
critical to secure and maintain research trust.
Research Agenda
Our findings, which are based on a sample primarily of men who inject drugs in poor, rural 
settings in Puerto Rico, might not be generalizable to other populations. While some 
concerns about privacy and confidentiality in social network studies might be shared by 
PWID in urban settings, or by users from different ethnic backgrounds, or in a different 
gender composition where women are more prevalent, more research is needed to document 
such continuities and changes. In addition, while this study focuses on the particular ethical 
issues raised by social network studies among PWID, the question of whether other 
vulnerable populations enrolled in similar studies might share the same concerns, requires 
further attention.
Educational Implications
Research findings suggest that researchers conducting social network studies, those involved 
in community-based research with people who inject drugs, and IRBs need to be aware of 
study participants’ views around privacy and confidentiality. Engaging participants in 
dialogue about the responsible conduct of research presents an opportunity to correct under- 
or overestimations of research vulnerabilities when such decisions are restricted to the 
perspectives of investigators or IRB members (Fisher, 1999).
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